Research Analysts Set Expectations for Neurocrine Biosciences, Inc.’s Q2 2019 Earnings (NBIX)

Share on StockTwits

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Oppenheimer boosted their Q2 2019 earnings estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, March 12th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings of $0.78 per share for the quarter, up from their prior forecast of $0.73. Oppenheimer has a “Outperform” rating and a $110.00 price target on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q3 2019 earnings at $0.69 EPS, FY2021 earnings at $5.35 EPS, FY2022 earnings at $6.79 EPS and FY2023 earnings at $8.75 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. The business had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 EPS.

Several other analysts also recently weighed in on the stock. ValuEngine upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, February 8th. Cantor Fitzgerald restated a “buy” rating and set a $121.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, December 12th. JPMorgan Chase & Co. downgraded shares of Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and upped their price target for the company from $97.00 to $100.00 in a research report on Wednesday, January 23rd. Stifel Nicolaus reduced their price target on shares of Neurocrine Biosciences from $115.00 to $17.07 and set a “buy” rating for the company in a research report on Wednesday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $102.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, January 15th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus price target of $102.56.

Shares of NASDAQ:NBIX opened at $82.97 on Thursday. The company has a market cap of $7.35 billion, a PE ratio of 377.14, a P/E/G ratio of 29.63 and a beta of 1.86. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98.

In other Neurocrine Biosciences news, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total value of $335,649.08. Following the transaction, the insider now directly owns 17,595 shares of the company’s stock, valued at approximately $1,550,471.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eiry Roberts sold 1,857 shares of the business’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $84.09, for a total transaction of $156,155.13. Following the completion of the transaction, the insider now directly owns 3,143 shares in the company, valued at $264,294.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,280 shares of company stock valued at $1,163,054. 4.30% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Eaton Vance Management increased its stake in Neurocrine Biosciences by 20.8% in the 4th quarter. Eaton Vance Management now owns 129,434 shares of the company’s stock valued at $9,243,000 after buying an additional 22,280 shares during the period. Dupont Capital Management Corp increased its stake in Neurocrine Biosciences by 160.8% in the 3rd quarter. Dupont Capital Management Corp now owns 12,912 shares of the company’s stock valued at $1,588,000 after buying an additional 7,961 shares during the period. Opera Trading Capital acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $449,000. Advisors Asset Management Inc. grew its stake in shares of Neurocrine Biosciences by 106.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,030 shares of the company’s stock worth $864,000 after purchasing an additional 3,628 shares during the period. Finally, Standard Life Aberdeen plc acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $16,815,000.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Story: Bull Market

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GeneNews  Stock Price Up 6.3%
GeneNews Stock Price Up 6.3%
Armadale Capital  Stock Price Down 7.6%
Armadale Capital Stock Price Down 7.6%
Caleres  Price Target Cut to $26.00 by Analysts at Loop Capital
Caleres Price Target Cut to $26.00 by Analysts at Loop Capital
G-III Apparel Group  Price Target Raised to $39.00 at Barclays
G-III Apparel Group Price Target Raised to $39.00 at Barclays
Vuzix  Stock Rating Upgraded by Zacks Investment Research
Vuzix Stock Rating Upgraded by Zacks Investment Research
HANG SENG BK LT/S  Rating Increased to Buy at UBS Group
HANG SENG BK LT/S Rating Increased to Buy at UBS Group


© 2006-2019 Ticker Report